Combining label-free proteomics with established mouse models of SMA led to the identification of Calreticulin and GRP75/Mortalin as protein biomarkers capable of reporting on disease progression in tissue samples of muscle and skin. This evidence concerns the gene CALR and proximal spinal muscular atrophy.